sparse_primary_supporting_bucket
Central evidence is high but primary supporting bucket is empty. Classification tiers may still be too coarse.
fulltoplow inflation risk
Richness
inflammatory bowel disease
Richness looks like a credible signal in inflammatory bowel disease, though some caution is still warranted.
Richness shows a strong literature footprint in inflammatory bowel disease, with substantial central evidence and broader supporting literature.
richness
Credibility score
65
Human translation
3/5
Reproducibility
4/5
Novelty
2/5
Actionability
5/5
Credibility 65Human translation 3/5Reproducibility 4/5Novelty 2/5Actionability 5/5
Why this scores the way it does
- strong central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- directionality and confounding still require curated review
Internal review flags
1 flagsPrimary central evidence
20 papersMicrobial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease.
2007Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation.
2015The American journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease.
2016Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease.
2018World journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease.
2019Scandinavian journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease.
2019Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota profile in patients with inflammatory bowel disease in Taiwan.
2021Journal of the Chinese Medical Association : JCMA
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease.
2021Cell host & microbe
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The Origin of Plasma-Derived Bacterial Extracellular Vesicles in Healthy Individuals and Patients with Inflammatory Bowel Disease: A Pilot Study.
2021Genes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms.
2021BMC gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Insight into gut dysbiosis of patients with inflammatory bowel disease and ischemic colitis.
2023Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota analyses of inflammatory bowel diseases from a representative Saudi population.
2023BMC gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Diarrheal-associated gut dysbiosis in cancer and inflammatory bowel disease patients is exacerbated by Clostridioides difficile infection.
2023Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Inflammatory bowel disease associated with primary sclerosing cholangitis is associated with an altered gut microbiome and bile acid profile.
2024Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Characterization of the salivary microbiome of adults with inflammatory bowel disease.
2025Journal of oral microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation.
2025Journal of Parkinson's disease
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The intestinal mucosa-associated microbiota in IBD-associated arthritis displays lower relative abundance of Roseburia intestinalis.
2025Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Whole Food Diet Induces Remission in Children and Young Adults With Mild to Moderate Crohn's Disease and Is More Tolerable Than Exclusive Enteral Nutrition: A Randomized Controlled Trial.
2025Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Distinct microbial mediators link diet to inflammation in Crohn's disease and ulcerative colitis.
2026Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal Mycobiota in Patients with Inflammatory Bowel Diseases and Extraintestinal Manifestations.
2024Gut microbes reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
12 papersAronia melanocarpa (Michx.) Elliott. attenuates dextran sulfate sodium-induced Inflammatory Bowel Disease via regulation of inflammation-related signaling pathways and modulation of the gut microbiota.
2022Journal of ethnopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Validation of the Anticolitis Efficacy of the Jian-Wei-Yu-Yang Formula.
2022Evidence-based complementary and alternative medicine : eCAM
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The pharmacological evidence of the chang-yan-ning formula in the treatment of colitis.
2022Frontiers in pharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Phylogeny and disease associations of a widespread and ancient intestinal bacteriophage lineage.
2024Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bioorthogonal conjugation and responsive nanocoating of probiotics for inflammatory bowel disease.
2024Journal of controlled release : official journal of the Controlled Release Society
Disease-relevant preclinical or model-based paper useful as supporting evidence.
A disturbed metabolite-GPCR axis is associated with microbial dysbiosis in IBD patients: Potential role of GPR109A in macrophages.
2024Biochimica et biophysica acta. Molecular basis of disease
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Failure of colonization following gut microbiota transfer exacerbates DSS-induced colitis.
2025Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Healthy microbiome-moving towards functional interpretation.
2025GigaScience
Disease-relevant preclinical or model-based paper useful as supporting evidence.
"One stone three birds": Andrographis paniculata -derived exosome-like nanoparticles mitigate dextran sulfate sodium-induced colitis.
2026Chinese medical journal
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Galactooligosaccharides Promote Gut Barrier Integrity and Exert Anti-Inflammatory Effects in DSS-Induced Colitis Through Microbiota Modulation.
2025International journal of molecular sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Annexin A1 levels affect microbiota in health and DSS-induced colitis/inflammatory bowel disease development.
2025Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Refined photobiomodulation therapy ameliorates inflammatory bowel disease via modulation of immune pathways and gut microbiota.
2026Journal of photochemistry and photobiology. B, Biology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
13 papersEpidemiologic clues to inflammatory bowel disease.
2010Current gastroenterology reports
Relevant review or meta-analysis for the signal-disease area.
Intestinal microbiota transplant - current state of knowledge.
2016Reumatologia
Relevant review or meta-analysis for the signal-disease area.
Diet and Gut Microbiota in Health and Disease.
2017Nestle Nutrition Institute workshop series
Relevant review or meta-analysis for the signal-disease area.
Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.
2018Alimentary pharmacology & therapeutics
Relevant review or meta-analysis for the signal-disease area.
Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
2018Journal of microbiology (Seoul, Korea)
Relevant review or meta-analysis for the signal-disease area.
Urbanization and the gut microbiota in health and inflammatory bowel disease.
2018Nature reviews. Gastroenterology & hepatology
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiome in Inflammatory Bowel Disease and Other Chronic Immune-Mediated Inflammatory Diseases.
2017Inflammatory intestinal diseases
Relevant review or meta-analysis for the signal-disease area.
Homeostasis and dysbiosis of the gut microbiome in health and disease.
2019Journal of biosciences
Relevant review or meta-analysis for the signal-disease area.
Microbiota and Drug Response in Inflammatory Bowel Disease.
2021Pathogens (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis.
2021Journal of clinical medicine
Relevant review or meta-analysis for the signal-disease area.
Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease.
2021Microorganisms
Relevant review or meta-analysis for the signal-disease area.
Assessing the Relationship between the Gut Microbiota and Inflammatory Bowel Disease Therapeutics: A Systematic Review.
2023Pathogens (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Gut microbiome, metabolome, host immunity associated with inflammatory bowel disease and intervention of fecal microbiota transplantation.
2023Journal of autoimmunity
Relevant review or meta-analysis for the signal-disease area.